# US 2024/0197731 A1 · Therapeutic compositions, combinations, and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197731 A1
- Document ID: US20240197731A1
- Status: Published application
- Kind: A1
- Application number: 18/416,354
- Filed: 2024-01-18
- Published: 2024-06-20
- Earliest claimed: 2019-09-13
- Assignees: The Institute of Cancer Research: Royal Cancer Hospital
- Applicants: The Institute of Cancer Research: Royal Cancer Hospital
- Inventors: Udai Banerji
- Web page: https://patentgrep.com/patent/US20240197731A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

A method of treating pancreatic cancer in a subject in need thereof, the method comprising orally administering to the subject an effective amount of CH5126766, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of defactinib, or a pharmaceutically acceptable salt thereof,
wherein CH5126766, or a pharmaceutically acceptable salt thereof, and defactinib, or a pharmaceutically acceptable salt thereof, are administered as a cycle comprising administering CH5126766, or a pharmaceutically acceptable salt thereof, and defactinib, or a pharmaceutically acceptable salt thereof, for three weeks and then not administering CH5126766, or a pharmaceutically acceptable salt thereof, and defactinib, or a pharmaceutically acceptable salt thereof, for one week.

### Claim 55 (depends on 54)

The method of claim 54, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered twice a week during the three weeks of administration.

### Claim 56 (depends on 54)

The method of claim 54, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered twice daily during the three weeks of administration.

### Claim 57 (depends on 54)

The method of claim 54, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 0.5 mg to 10 mg per administration.

### Claim 58 (depends on 54)

The method of claim 54, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 0.5 mg to 5 mg per administration.

### Claim 59 (depends on 58)

The method of claim 58, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 3.2 mg per administration.

### Claim 60 (depends on 58)

The method of claim 58, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 4 mg per administration.

### Claim 61 (depends on 54)

The method of claim 54, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered at a dose of 100 mg to 500 mg per administration.

### Claim 62 (depends on 61)

The method of claim 61, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered at a dose of 200 mg per administration.

### Claim 63 (depends on 61)

The method of claim 61, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered at a dose of 400 mg per administration.

### Claim 64 (depends on 54)

The method of claim 54, wherein the cancer is characterized as having a mutation in EGFR, FGFR, ALK, ROS1, PI3K, NF-1, BRAF, HRAS, KRAS, or NRAS.

### Claim 65 (depends on 54)

The method of claim 54, wherein the cancer is characterized as having a mutation in RAS, BRAF, or NF-1.

### Claim 66 (depends on 54)

The method of claim 54, wherein the cancer is characterized as having a mutation in RAS.

### Claim 67 (depends on 66)

The method of claim 66, wherein the mutation in RAS is a HRAS, KRAS, or NRAS mutation.

### Claim 68 (depends on 66)

The method of claim 66, wherein the mutation in RAS is HRAS.

### Claim 69 (depends on 66)

The method of claim 66, wherein the mutation in RAS is KRAS.

### Claim 70 (depends on 66)

The method of claim 66, wherein the mutation in RAS is NRAS.

### Claim 71 (depends on 54)

The method of claim 54, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is a potassium salt of CH5126766.

### Claim 72 (depends on 54)

The method of claim 54, wherein defactinib, or a pharmaceutically acceptable salt thereof, is a hydrochloride salt of defactinib.

### Claim 73 (depends on 54)

The method of claim 54, wherein the pancreatic cancer is metastatic.

### Claim 74 (depends on 73)

The method of claim 73, wherein the pancreatic cancer is metastatic pancreatic adenocarcinoma.

### Claim 75 (depends on 54)

The method of claim 54, wherein the pancreatic cancer is primary tumor.

### Claim 76 (depends on 54)

The method of claim 54, further comprising administering to the subject one or more additional therapies.

### Claim 77 (depends on 76)

The method of claim 76, wherein the one or more additional therapies are selected from the group consisting of chemotherapies, antibody therapies, immunotherapies, and hormonal therapies.

### Claim 78 (depends on 76)

The method of claim 76, wherein the one or more additional therapies are chemotherapeutic agents.

### Claim 79 (depends on 76)

The method of claim 76, comprising administering to the subject one or two additional therapies.

### Claim 80 (depends on 79)

The method of claim 79, wherein the additional therapies are selected from the group consisting of gemcitabine and nab-paclitaxel.

### Claim 81 (depends on 79)

The method of claim 79, wherein the additional therapies are selected from the group consisting of aclarubicin, actinomycin, alitretmon, altretamine, ammopterin, aminolevulinic acid, amrubicin, amsacrine, anagrelide, arsenic trioxide, asparaginase, atrasentan, belotecan, bexarotene, endamustine, bleomycin, bortezomib, busulfan, camptothecin, capecitabine, carboplatin, carboquone, carmofur, carmustine, celecoxib, chlorambucil, chlormethine, cisplatin, cladribine, clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, demecolcine, docetaxel, doxorubicin, efaproxiral, elesclomol, elsamitrucin, enocitabine, epirubicin, estramustine, etoglucid, etoposide, floxundine, fludarabine, fluorouracil (SFU), fotemustine, gemcitabine, ghadel implants, hydroxycarbamide, hydroxyurea, idarubicin, ifosfamide, irinotecan, irofulven, ixabepilone, Jarotaxel, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lonidamine, lomustine, lucanthone, mannosulfan, masoprocol, melphalan, mercaptopurine, mesna, methotrexate, methyl aminolevulinate, mitobronitol, mitoguazone, mitotane, mitomycin, mitoxantrone, nedaplatin, nimustine, oblimersen, omacetaxine, ortataxel, oxaliplatin, paclitaxel, pegaspargase, pemetrexed, pentostatin, pirarubicin, pixantrone, plicamycin, porfimer sodium, prednimustine, procarbazine, raltitrexed, ranimustine, rubitecan, sapacitabine, semustine, sitimagene ceradenovec, strataplatin, streptozocin, talaporfin, tegafur-uracil, temoporfm, temozolomide, teniposide, tesetaxel, testolactone, tetranitrate, thiotepa, tiazofurine, tioguanine, tipifamib, topotecan, trabectedin, triaziquone, triethylenemelamine, triplatin, tretinoin, treosulfan, trofosfamide, uramustine, valrubicin, verteporfin, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vorinostat, and zorubicin.
